Long-Acting PrEP Drug Success: Gilead's Phase 3 Trials Show Promise for HIV Prevention
Long-Acting PrEP Drug Breakthrough
In recent developments, Gilead's long-acting PrEP drug, lenacapavir, has shown exceptional efficacy. In a large study of more than 3,000 participants, this innovative treatment delivered a stunning 96% reduction in HIV infections compared to background rates. This advancement represents a pivotal moment in the fight against HIV.
Study Insights
The phase 3 trial results highlight how lenacapavir can revolutionize HIV prevention through its twice-yearly dosing regimen, providing a new avenue for individuals at risk of infection.
- Over 3,000 participants involved
- 96% reduction in infections
- Potential launch in 2025
For more details, please visit the source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.